Uncategorized

Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms

Published

on

Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version